IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 39.2GRADE D
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
7.1%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, LIGAND PHARMACEUTICALS INC (LGND) receives a "Hold" rating with a composite score of 44.4/100, ranked #898 out of 4446 stocks. Key factor scores: Quality 39/100, Value 45/100, Momentum 63/100. This is quantitative analysis only — not investment advice.
LIGAND PHARMACEUTICALS INC (LGND) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does LIGAND PHARMACEUTICALS INC Do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California. LIGAND PHARMACEUTICALS INC (LGND) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John L. Higgins and employs approximately 80 people, headquartered in San Diego, California. With a market capitalization of $4.0B, LGND is one of the notable companies in the Healthcare sector.
LIGAND PHARMACEUTICALS INC (LGND) Stock Rating — Hold (April 2026)
As of April 2026, LIGAND PHARMACEUTICALS INC receives a Hold rating with a composite score of 44.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.LGND ranks #898 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, LIGAND PHARMACEUTICALS INC ranks #63 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
LGND Stock Price and 52-Week Range
LIGAND PHARMACEUTICALS INC (LGND) currently trades at $204.92. The stock lost $0.72 (0.4%) in the most recent trading session. The 52-week high for LGND is $227.92, which means the stock is currently trading -10.1% from its annual peak. The 52-week low is $93.58, putting the stock 119.0% above its annual trough. Recent trading volume was 277K shares, suggesting relatively thin trading activity.
Is LGND Overvalued or Undervalued? — Valuation Analysis
LIGAND PHARMACEUTICALS INC (LGND) carries a value factor score of 45/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 56.42x, compared to the Healthcare sector average of 23.63x — a premium of 139%. The price-to-book ratio stands at 4.02x, versus the sector average of 2.75x. The price-to-sales ratio is 15.72x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, LGND trades at 134.97x EV/EBITDA, versus 6.34x for the sector.
Overall, LGND's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
LIGAND PHARMACEUTICALS INC Profitability — ROE, Margins, and Quality Score
LIGAND PHARMACEUTICALS INC (LGND) earns a quality factor score of 39/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 7.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 4.7% versus the sector average of -33.1%.
On a margin basis, LIGAND PHARMACEUTICALS INC reports gross margins of 96.7%, compared to 71.5% for the sector. The operating margin is -2.1% (sector: -66.1%). Net profit margin stands at 1.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 178.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
LGND Debt, Balance Sheet, and Financial Health
LIGAND PHARMACEUTICALS INC has a debt-to-equity ratio of 53.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 22.23x, indicating strong short-term liquidity. Cash and equivalents stand at $139M.
LGND has a beta of 1.08, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for LIGAND PHARMACEUTICALS INC is 72/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
LIGAND PHARMACEUTICALS INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, LIGAND PHARMACEUTICALS INC reported revenue of $260M and earnings per share (EPS) of $6.44. Net income for the quarter was $72M. Operating income came in at $30M.
In FY 2025, LIGAND PHARMACEUTICALS INC reported revenue of $268M and earnings per share (EPS) of $6.44. Net income for the quarter was $124M. Revenue grew 60.4% year-over-year compared to FY 2024. Operating income came in at $41M.
In Q3 2025, LIGAND PHARMACEUTICALS INC reported revenue of $115M and earnings per share (EPS) of $5.99. Net income for the quarter was $117M. Revenue grew 122.8% year-over-year compared to Q3 2024. Operating income came in at $55M.
In Q2 2025, LIGAND PHARMACEUTICALS INC reported revenue of $48M and earnings per share (EPS) of $0.25. Net income for the quarter was $5M. Revenue grew 14.7% year-over-year compared to Q2 2024. Operating income came in at $8M.
Over the past 8 quarters, LIGAND PHARMACEUTICALS INC has demonstrated a growth trajectory, with revenue expanding from $42M to $260M. Investors analyzing LGND stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
LGND Dividend Yield and Income Analysis
LIGAND PHARMACEUTICALS INC (LGND) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
LGND Momentum and Technical Analysis Profile
LIGAND PHARMACEUTICALS INC (LGND) has a momentum factor score of 63/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 9/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
LGND vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing LGND against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full LGND vs S&P 500 (SPY) comparison to assess how LIGAND PHARMACEUTICALS INC stacks up against the broader market across all factor dimensions.
LGND Next Earnings Date
No upcoming earnings date has been announced for LIGAND PHARMACEUTICALS INC (LGND) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy LGND? — Investment Thesis Summary
LIGAND PHARMACEUTICALS INC presents a balanced picture with arguments on both sides. The quality score of 39/100 flags below-average profitability. Price momentum is positive at 63/100, suggesting the trend favors buyers. Low volatility (stability score 72/100) reduces downside risk.
In summary, LIGAND PHARMACEUTICALS INC (LGND) earns a Hold rating with a composite score of 44.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on LGND stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
LIGAND PHARMACEUTICALS INC (LGND) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Ligand Pharmaceuticals Inc. (LGND) has been rated a Hold by the BCR model, with a composite score of 44.3/100 and a rank of #694 out of 4,446 companies. While the company has strong profitability and stability, its investment and value metrics are relatively weak, indicating potential challenges in sustaining its growth and profitability in the long run. The key takeaway is that LGND's current valuation may not be fully justified by its fundamental performance, and investors should closely monitor the company's ability to execute on its strategic initiatives and navigate the competitive landscape.
Business Strategy & Overview
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop new medicines. The company's commercial programs include a diverse portfolio of products used to treat a range of diseases, such as multiple myeloma, COVID-19, osteoporosis, and various types of cancer. Additionally, Ligand provides its Captisol technology, which is used to enhance the solubility and stability of active pharmaceutical ingredients, to other pharmaceutical companies.
Ligand's strategy revolves around leveraging its platform of technologies, including Captisol, to partner with other pharmaceutical and biotechnology companies, providing them with access to Ligand's intellectual property and expertise in drug development. This approach allows Ligand to generate revenue through upfront payments, milestone payments, and royalties on product sales, without bearing the full cost and risk of drug development and commercialization.
The company's pipeline includes a mix of late-stage and early-stage programs, with a focus on therapeutic areas such as oncology, inflammation, and rare diseases. Ligand's ability to identify and acquire promising technologies, as well as its track record of successful partnerships, has been a key driver of its growth and profitability.
Execution Benchmarks audit
Revenue Growth
YOY expansion rate
178.0%
Sector: 10.6%
+1573% VS SCTR
Economic Moat Analysis
Ligand Pharmaceuticals possesses a narrow economic moat, primarily driven by its intellectual property and expertise in drug development technologies. The company's Captisol technology, which is used to enhance the solubility and stability of active pharmaceutical ingredients, has been a significant source of competitive advantage. Captisol is protected by a robust patent portfolio, and its use is required for several of Ligand's commercial products, creating a barrier to entry for potential competitors.
Additionally, Ligand's partnerships with pharmaceutical and biotechnology companies, which provide it with revenue streams through upfront payments, milestone payments, and royalties, further strengthen its competitive position. These partnerships are often based on long-term agreements and create switching costs for the partner companies, making it difficult for them to easily replace Ligand's technologies and services.
However, Ligand's moat is not as wide as some of its peers in the pharmaceutical industry, as the company's technologies can be replicated, and its partners may develop in-house capabilities or seek alternative solutions over time. The company's ability to continuously innovate and expand its technology portfolio will be crucial in maintaining and widening its competitive advantage.
Financial Health & Profitability
Ligand Pharmaceuticals has exhibited a mixed financial performance in recent years. The company's revenue growth has been volatile, with a significant increase in the trailing twelve months (TTM) to $268.09 million, compared to $131.31 million in the previous fiscal year. This growth has been driven by the successful commercialization of products like Veklury (for the treatment of COVID-19) and Rylaze (for the treatment of acute lymphoblastic leukemia).
However, the company's profitability metrics have been less impressive. Ligand's gross margin of 96.7% is significantly higher than the sector average of 71.9%, indicating strong pricing power and efficient operations. But its operating margin of -2.1% is well below the sector average of -65.2%, reflecting the company's high research and development expenses, as well as its strategic investments in expanding its pipeline and technology platform.
The company's balance sheet appears relatively strong, with a current ratio of 22.23 and a debt-to-equity ratio of 53.00, which is higher than the sector average of 30.00. This suggests that Ligand has ample liquidity to fund its operations and investments, but may also indicate a higher reliance on debt financing.
Overall, Ligand's financial health is a mixed bag, with strong revenue growth and profitability, but potentially suboptimal capital allocation and investment efficiency compared to its peers. Investors should closely monitor the company's ability to translate its technological advantages into consistent and sustainable financial performance.
Valuation Assessment
Ligand Pharmaceuticals' current valuation appears to be on the higher end compared to its industry peers. The company's P/E ratio of 31.8x is significantly higher than the sector average of 24.3x, and its EV/EBITDA ratio of 24.9x is substantially above the sector average of 6.4x.
However, it's important to note that Ligand's recent financial performance has been volatile, with significant swings in profitability and cash flow generation. The company's TTM net income of $124.45 million and negative free cash flow may not fully justify its current valuation, particularly when compared to the broader healthcare sector.
Additionally, Ligand's strong revenue growth of 178.0% in the TTM period, compared to the sector average of 10.7%, could suggest that the market is pricing in expectations of continued robust growth. Investors should closely monitor the company's ability to translate this growth into sustainable profitability and cash flow generation, as this will be a key driver of its long-term valuation.
Overall, Ligand's current valuation appears to be on the higher side, and investors should carefully consider the company's ability to execute on its strategic initiatives and maintain its competitive edge in the rapidly evolving pharmaceutical industry.
Risk & Uncertainty
Ligand Pharmaceuticals faces several key risks and uncertainties that could impact its long-term performance. One of the primary risks is the company's heavy reliance on its partnerships and licensing agreements with other pharmaceutical and biotechnology companies. While these partnerships have been a critical driver of Ligand's growth, they also expose the company to the success and strategic decisions of its partners. If any of Ligand's key partners were to experience setbacks in their product development or commercialization efforts, it could have a significant negative impact on Ligand's financial performance.
Another risk factor is the highly competitive and rapidly evolving nature of the pharmaceutical industry. Ligand's technologies, such as Captisol, could face competition from alternative solutions developed by other companies, or its partners may choose to develop in-house capabilities, reducing Ligand's competitive advantage and revenue streams.
Additionally, Ligand's business model is heavily dependent on its ability to identify and acquire promising technologies, as well as successfully integrate and commercialize them. Any missteps in this process could result in suboptimal returns on the company's investments and undermine its growth trajectory.
Bulls Say / Bears Say
The Bull Case
BULL VIEWLigand's platform of drug development technologies, particularly its Captisol technology, provide a strong competitive advantage and potential for continued growth through partnerships and licensing agreements.
BULL VIEWThe company's diverse portfolio of commercial products, including successful launches of Veklury and Rylaze, demonstrate its ability to translate its technologies into revenue-generating assets.
The Bear Case
BEAR VIEWLigand's reliance on partnerships and licensing agreements exposes the company to significant risks, as the success of its business is largely dependent on the performance and strategic decisions of its partners.
BEAR VIEWThe company's volatile financial performance, with swings in profitability and cash flow generation, raises concerns about the sustainability of its growth and the justification of its current valuation.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score LGND and 4,400+ other equities.
LIGAND PHARMACEUTICALS INC exhibits a 765% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
4.7%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
96.7%
Sector: 71.5%
Operating Margin
Core business profitability
-2.1%
Sector: -66.1%
Net Margin
Bottom-line profitability
1.1%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
